Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 21fludarabine phosphate 18Whole-Body Irradiation 17Methotrexate 17Tacrolimus 15Peripheral Blood Stem Cell Transplantation 15Mycophenolic Acid 13Dexamethasone 11Vincristine 10Etoposide 10Antilymphocyte Serum 10Calcium Dobesilate 9Busulfan 9Rituximab 8Doxorubicin 8merphos 7Filgrastim 7Cytarabine 7Sirolimus 6Prednisone 6Melphalan 6Granulocyte Colony-Stimulating Factor 6Cyclosporine 6pegaspargase 5dexamethasone acetate 5dexamethasone 21-phosphate 5prednylidene 4deltacortene 4auricularum 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × CVAD protocol × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡